Jeff Yass’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $399M | Sell |
5,692,300
-1,341,300
| -19% | -$69.4M | 0.03% | 370 |
|
|
2026
Q1 | $357M | Sell |
7,033,600
-4,301,800
| -38% | -$201M | 0.04% | 346 |
|
|
2025
Q4 | $334M | Buy |
11,335,400
+4,201,800
| +59% | +$114M | 0.04% | 370 |
|
|
2025
Q3 | $184M | Buy |
7,133,600
+1,726,900
| +32% | +$48.2M | 0.02% | 573 |
|
|
2025
Q2 | $149M | Buy |
5,406,700
+849,300
| +19% | +$22.4M | 0.02% | 561 |
|
|
2025
Q1 | $129M | Sell |
4,557,400
-1,690,800
| -27% | -$60M | 0.02% | 544 |
|
|
2024
Q4 | $260M | Buy |
6,248,200
+3,858,800
| +161% | +$184M | 0.04% | 345 |
|
|
2024
Q3 | $160M | Buy |
2,389,400
+26,600
| +1% | +$2.44M | 0.03% | 468 |
|
|
2024
Q2 | $281M | Sell |
2,362,800
-345,500
| -13% | -$43.7M | 0.05% | 264 |
|
|
2024
Q1 | $289M | Sell |
2,708,300
-624,800
| -19% | -$63M | 0.05% | 301 |
|
|
2023
Q4 | $331M | Buy |
3,333,100
+113,300
| +4% | +$9.53M | 0.06% | 252 |
|
|
2023
Q3 | $333M | Buy |
3,219,800
+1,077,400
| +50% | +$120M | 0.07% | 221 |
|
|
2023
Q2 | $260M | Sell |
2,142,400
-341,600
| -14% | -$45.6M | 0.05% | 278 |
|
|
2023
Q1 | $381M | Sell |
2,484,000
-1,539,800
| -38% | -$254M | 0.08% | 187 |
|
|
2022
Q4 | $723M | Buy |
4,023,800
+2,196,200
| +120% | +$359M | 0.18% | 81 |
|
|
2022
Q3 | $216M | Sell |
1,827,600
-668,400
| -27% | -$101M | 0.06% | 278 |
|
|
2022
Q2 | $357M | Sell |
2,496,000
-1,663,200
| -40% | -$238M | 0.09% | 168 |
|
|
2022
Q1 | $716M | Sell |
4,159,200
-1,180,500
| -22% | -$199M | 0.12% | 109 |
|
|
2021
Q4 | $1.36B | Sell |
5,339,700
-1,200,300
| -18% | -$351M | 0.2% | 69 |
|
|
2021
Q3 | $2.52B | Buy |
6,540,000
+416,300
| +7% | +$154M | 0.34% | 34 |
|
|
2021
Q2 | $1.44B | Buy |
6,123,700
+600
| +0% | +$107K | 0.2% | 60 |
|
|
2021
Q1 | $802M | Sell |
6,123,100
-538,000
| -8% | -$78M | 0.13% | 122 |
|
|
2020
Q4 | $696M | Buy |
6,661,100
+3,336,100
| +100% | +$338M | 0.11% | 122 |
|
|
2020
Q3 | $235M | Buy |
3,325,000
+735,100
| +28% | +$51.3M | 0.05% | 299 |
|
|
2020
Q2 | $166M | Buy |
2,589,900
+1,246,900
| +93% | +$68.3M | 0.04% | 348 |
|
|
2020
Q1 | $40.2M | Buy |
1,343,000
+1,149,600
| +594% | +$26.4M | 0.01% | 755 |
|
|
2019
Q4 | $3.78M | Sell |
193,400
-54,900
| -22% | -$974K | ﹤0.01% | 3360 |
|
|
2019
Q3 | $3.95M | Buy |
248,300
+69,500
| +39% | +$1.03M | ﹤0.01% | 3054 |
|
|
2019
Q2 | $2.62M | Sell |
178,800
-18,200
| -9% | -$391K | ﹤0.01% | 3678 |
|
|
2019
Q1 | $4.01M | Buy |
+197,000
| New | +$3.66M | ﹤0.01% | 2723 |
|
Other funds holding MRNA
TP
Jeff Yass's MRNA Position: Q2 2026 in Review
Jeff Yass increased its Moderna (MRNA) stake by 552% in Q2 2026, buying an estimated $15.7M and bringing the position to 357,774 shares worth $25.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.
Jeff Yass first reported a position in MRNA in Q4 2018 and has held it in 29 quarters since. The position peaked at $270M in Q3 2021. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Jeff Yass held 357,774 shares of Moderna worth $25.1M as of Q2 2026.
- Jeff Yass bought 302,934 Moderna shares in Q2 2026, an estimated $15.7M.
- Moderna made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #2212 holding.
- Jeff Yass first reported a position in Moderna in Q4 2018 and has held it in 29 quarters since.
- Jeff Yass's Moderna position peaked at $270M in Q3 2021.
- 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.